The United States Patent and Trademark Office (USPTO) has issued patent US12583902B2 for "DNA-binding domain transactivators and uses thereof." The patent, assigned to the University of Massachusetts, covers recombinant adeno-associated viruses (rAAVs) that contain a nucleic acid encoding a fusion protein. This fusion protein comprises a DNA-binding domain and a transcriptional regulator domain, intended to modify the expression of target genes within cells.

This patent grant is primarily an intellectual property matter and does not impose direct compliance obligations on regulated entities. However, it may impact research and development activities in the biotechnology and pharmaceutical sectors, particularly concerning gene therapy and gene expression modification. Companies operating in these areas should be aware of this patent's scope when developing related technologies or products to avoid potential infringement issues.